

REMARKS/ARGUMENTS

In order to expedite prosecution, Applicants have amended claim 1 and cancelled claims 9, 14-15, 17, 25 and 26. Claim 9 has been incorporated into claim 1. No new matter has been added to these claims.

35 USC 112 Rejection, first and second paragraph

Applicants have cancelled claims 15 and 17 to overcome the 112 rejections for failing to particularly point out and claim the subject matter and for failing to comply with the written description requirement.

Claims 1, 4-7, 9-14 and 9-28 under 35 USC 112, first paragraph, as failing to comply with the written description requirement. In reply, Applicants have amended claim 1 and cancelled claims 9, 15, 17 and 25-26.

Additionally, claims 1, 4-7, and 9-28 under 35 USC 112, first paragraph are rejected because the specification does not provide enablement for any or all the iodonium salt and fluoridation in claim 1 and compounds with diverse structure embraced in claims 15 and 17. Applicants have amended claim 1 and cancelled claims 9, 15, 17 and 25-26.

In view of the amendments and remarks, hereinabove, Applicants respectfully submit that the instant application and claims are patentably distinct over the prior art. Favorable action thereon is respectfully requested.

Appl. No. 10/559,878
Amdt. Dated December 3, 2010
Reply to Office Action of September 3, 2010

The Examiner is invited to telephone the undersigned in order to resolve any issues that might arise and to promote the efficient examination of the current application.

Respectfully submitted,

/Craig Bohlken/

Craig Bohlken
Reg. No. 52,628

GE Healthcare, Inc.
101 Carnegie Center
Princeton, NJ 08540
Phone (609) 514-6530
I:\IP\Response to Office Action\PZ\PZ0414 (12-03-2010).doc